Reclast Dosing for Osteoporosis Treatment

Standard Dosing Schedule

The American College of Physicians recommends zoledronic acid 5 mg via intravenous infusion once per year for osteoporosis treatment, with adequate hydration before administration and monitoring of renal function 1
The infusion must be administered over at least 15 minutes to minimize acute phase reactions and renal toxicity 1

The American College of Physicians recommends treating osteoporotic women with pharmacologic therapy for 5 years, with consideration for discontinuation after 3-5 years if BMD is stable and short-term fracture risk is low 1
For patients with high fracture risk, extending treatment for up to 6 years may be appropriate 1
At the time of disease relapse or new fractures, retreatment on the annual schedule should be initiated 2

For premenopausal women on ovarian suppression with aromatase inhibitors, zoledronic acid 4 mg should be administered every 6 months to prevent rapid bone loss 1
For postmenopausal women on aromatase inhibitors, zoledronic acid 4 mg every 6 months has been used in clinical trials, though the standard osteoporosis dose of 5 mg annually is also effective 1
For osteopenia in high-risk patients, zoledronic acid 5 mg every 2 years may be considered, though this is not FDA-approved and should only be used in carefully selected cases 1

After 1-2 years of standard dosing, less-frequent administration has been evaluated and may be considered in patients with responsive or stable disease 2

The National Comprehensive Cancer Network recommends correcting any vitamin D deficiency before treatment to avoid hypocalcemia, and optimizing calcium and vitamin D intake before initiating therapy 1
A dental examination and prophylactic measures should be completed before starting therapy to reduce the risk of osteonecrosis of the jaw 1
Serum creatinine should be monitored before each dose, as zoledronic acid is contraindicated if creatinine clearance is less than 30-35 mL/min 1

Do not infuse faster than 15 minutes, as this increases acute phase reactions and renal toxicity 1
Do not use in patients with uncorrected hypocalcemia or vitamin D deficiency 1
Do not administer to patients with severe renal impairment (CrCl <30-35 mL/min) 1